Table 1.

Estimated doses to healthy organs, brain lesions, and extracranial metastases

Organ/lesionDmean, Gy/GBqRange, Gy/GBq
Adrenals0.1920.153–0.229
Brain0.0760.064–0.086
Breasts0.1420.113–0.173
Gall bladder wall0.1940.158–0.232
Lower large intestine wall0.1780.144–0.221
Small intestine0.1780.149–0.213
Stomach wall0.1780.143–0.218
Upper large intestine wall0.1820.147–0.225
Heart wall0.2050.107–0.318
Kidneys0.5530.397–0.791
Liver0.2970.229–0.346
Lungs0.3400.224–0.293
Muscle0.1570.127–0.193
Ovaries0.2040.188–0.224
Pancreas0.1950.156–0.235
Bone red marrow0.2010.168–0.256
Osteogenic cells0.3260.257–0.411
Skin0.1320.106–0.163
Spleen0.2970.172–0.413
Testes0.1330.124–0.143
Thymus0.1690.133–0.204
Thyroid2.6480.807–5.650
Urinary bladder wall0.1680.142–0.201
Uterus0.2020.187–0.222
Total body0.1710.138–0.206
Effective dose0.3150.220–0.481
Brain lesions0.3760.099–1.370
Extracranial lesions1.4080.153–5.380

NOTE: The dose of radioactivity to the various organs (normalized per GBq of administered 131I-labeled antibody) was calculated as described in the Materials and Methods. Please note the large range of values in the brain and extracranial lesions, which are in stark contrast with the extremely narrow range observed for the normal organs. The high variability observed for the thyroid reflects a poor compliance of patients for their premedication with Lugol solution during the diagnostic phase of the study.